AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8236072 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF measurement at two hourly intervals during waking hours for one week
Number of subjects: 273
Study 8236072 — intervention group
Group type: COMPARATOR
Intervention: Bronchial challenge test measuring the provocative dose of methacholine producing a 20% fall in FEV1 (PD20)
Number of subjects: 273
Study 3323648 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulin G
Number of subjects: 288
Study 3323648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 288
Study 31862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals should set an example and not smoke
Number of subjects: 1047
Study 31862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals should provide smoking cessation support
Number of subjects: 1047
Study 31862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitals should provide smoking cessation treatments
Number of subjects: 1047
Study 31862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitals are role model organizations in compliance with the smoke-free legislation
Number of subjects: 1047
Study 31862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization is a perfect moment to quit smoking
Number of subjects: 1047
Study 31862532 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations of receiving smoking cessation interventions
Number of subjects: 1047
Study 29473353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (acupuncture at five mind points + modified kidney qi decoction)
Number of subjects: 180
Study 29473353 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group (simple acupuncture at five mind points)
Number of subjects: 180
Study 29473353 — intervention group
Group type: COMPARATOR
Intervention: Herb group (simple modified kidney qi decoction)
Number of subjects: 180
Study 27059278 — intervention group
Group type: EXPERIMENTAL
Intervention: High amplitude burst SCS
Number of subjects: 40
Study 27059278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low amplitude burst SCS
Number of subjects: 40
Study 27059278 — intervention group
Group type: COMPARATOR
Intervention: Tonic SCS
Number of subjects: 40
Study 27059278 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient preference
Number of subjects: 40
Study 25625720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket revision (Group A)
Number of subjects: 258
Study 25625720 — intervention group
Group type: COMPARATOR
Intervention: No pocket revision (Group B)
Number of subjects: 258
Study 25625720 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 258
Study 23856331 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted split virion vaccine (3.75 μg HA/AS03)
Number of subjects: 4048
Study 23856331 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (15 μg HA)
Number of subjects: 4048
Study 23856331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 4048
Study 20495781 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpyloric feeding (TPF)
Number of subjects: 104
Study 20495781 — intervention group
Group type: COMPARATOR
Intervention: Gastric feeding (GF)
Number of subjects: 104
Study 18386547 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 49
Study 18386547 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 180 mg
Number of subjects: 49
Study 18386547 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 18386547 — intervention group
Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg and 180 mg
Number of subjects: 49
Study 16098944 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory distractor (D) sequence during self-paced tapping
Number of subjects: 0
Study 16098944 — intervention group
Group type: EXPERIMENTAL
Intervention: Isochronous auditory target (T) sequence
Number of subjects: 0
Study 16098944 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no auditory distractor)
Number of subjects: 0
Study 14606782 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2) plus H2O paste
Number of subjects: 140
Study 14606782 — intervention group
Group type: COMPARATOR
Intervention: Dry cotton pellet
Number of subjects: 140
Study 11129710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Skincare (BSC) - 1.2 g
Number of subjects: 3
Study 11129710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosiguard towelletes with 0.574 g PMD
Number of subjects: 3
Study 11129710 — intervention group
Group type: EXPERIMENTAL
Intervention: Deet (15% diethyl-3-methylbenzamide, Tabard lotion) - 0.5 g
Number of subjects: 3
Study 11129710 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (right arm)
Number of subjects: 3
Study 8770963 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (MgCO3) at a dose of 465 +/- 52 mg/day elemental Mg
Number of subjects: 0
Study 8770963 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) at the usual dose
Number of subjects: 0
Study 8770963 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium carbonate (MgCO3)
Number of subjects: 0
Study 1443141 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal electrical nerve stimulation (15 Hz, 100 microseconds)
Number of subjects: 12
Study 1443141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical stimuli (balloon distension)
Number of subjects: 12
Study 1443141 — intervention group
Group type: COMPARATOR
Intervention: Jejunal slow wave activity
Number of subjects: 12
Study 2857677 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion for 72 hours
Number of subjects: 95
Study 2857677 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 95
Study 30785624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for BDD (CBT‐BDD)
Number of subjects: 120
Study 30785624 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy
Number of subjects: 120
Study 29477262 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 180
Study 27393697 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 455
Study 27393697 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 455
Study 24914425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical tooth cleaning by toothbrush and dental floss once a day
Number of subjects: 54
Study 24914425 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study 22897549 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced services funded by the AFL program
Number of subjects: 1038
Study 22897549 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1038
Study 20420943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ng/kg Escherichia coli endotoxin (LPS)
Number of subjects: 10
Study 20420943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17659062 — intervention group
Group type: EXPERIMENTAL
Intervention: MST plus standard care (SC)
Number of subjects: 127
Study 17659062 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC) alone
Number of subjects: 127
Study 16089135 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional medicine plus tongxinluo capsule (TXL)
Number of subjects: 112
Study 16089135 — intervention group
Group type: COMPARATOR
Intervention: Conventional medicine (Control Group)
Number of subjects: 112
Study 12017350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine treatment
Number of subjects: 2791
Study 12017350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2791
Study 10084583 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral estradiol daily
Number of subjects: 19
Study 10084583 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol daily
Number of subjects: 19
Study 10084583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7745019 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-supplemented diet for 4 weeks
Number of subjects: 97
Study 7745019 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructed to eat as usual)
Number of subjects: 97
Study 2166619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexon Plus
Number of subjects: 84
Study 2166619 — intervention group
Group type: COMPARATOR
Intervention: Maxon
Number of subjects: 84
Study 7195483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine and domperidone
Number of subjects: 20
Study 7195483 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (control for nausea and vomiting)
Number of subjects: 20
Study 31847908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical sirolimus applied for 12 weeks
Number of subjects: 55
Study 31847908 — intervention group
Group type: COMPARATOR
Intervention: Topical vehicle applied for 12 weeks
Number of subjects: 55
Study 31847908 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic passage of sirolimus measured at weeks 6, 12, and 20, and at week 16 for CMLMs ≥ 900 cm2
Number of subjects: 55
Study 30084133 — intervention group
Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI)
Number of subjects: 221
Study 30084133 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH‐OUT
Number of subjects: 221
Study 26265727 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalex Active 50+ (1g DHA, 160 mg eicosapentaenoic acid, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20mg d‐α tocopherol, 1mg folic acid, and 20 µg vitamin B12 per day)
Number of subjects: 27
Study 26265727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24443035 — intervention group
Group type: EXPERIMENTAL
Intervention: Duty-cycled multi-electrode radiofrequency ablation (PVAC)
Number of subjects: 161
Study 24443035 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigated point-by-point radiofrequency ablation (CPVI)
Number of subjects: 161
Study 22522786 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises (performed twice a week for 3 months, starting at 60% of 1MR and progressing to 85%)
Number of subjects: 58
Study 22522786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 58
Study 18469366 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Youth Places (HYP) intervention
Number of subjects: 1582
Study 18469366 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-HYP schools)
Number of subjects: 1582
Study 17635424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse manoeuvre for inserting the Airtraq laryngoscope
Number of subjects: 40
Study 17635424 — intervention group
Group type: COMPARATOR
Intervention: Standard technique for inserting the Airtraq laryngoscope
Number of subjects: 40
Study 15159711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 guideline implementation strategies of increasing intensity
Number of subjects: 0
Study 15159711 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices including assessment of arterial oxygenation, collection of blood cultures, timely initiation of appropriate empiric antibiotic therapy
Number of subjects: 0
Study 11861264 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha plus LDAC
Number of subjects: 538
Study 11861264 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha
Number of subjects: 538
Study 10211597 — intervention group
Group type: EXPERIMENTAL
Intervention: PEIT-1 (1 session with a single intranodular injection of sterile 98% ethanol)
Number of subjects: 60
Study 10211597 — intervention group
Group type: EXPERIMENTAL
Intervention: PEIT-3 (3 weekly sessions with 1 injection of sterile 98% ethanol)
Number of subjects: 60
Study 7623249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) root conditioning and fibrin-fibronectin sealing system (FFSS) application
Number of subjects: 8
Study 7623249 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with gingival flap surgery with barrier membrane alone
Number of subjects: 8
Study 2533041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg single dose)
Number of subjects: 12
Study 2533041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 779058 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 40
Study 779058 — intervention group
Group type: COMPARATOR
Intervention: 100 mg tilidine hydrochloride
Number of subjects: 40
Study 30540657 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 360
Study 30540657 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study 28121722 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of EPA and 400 mg of DHA per day for 18 weeks
Number of subjects: 272
Study 28121722 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil capsules (placebo) per day for 18 weeks
Number of subjects: 272
Study 25654366 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telehealth hospitalization
Number of subjects: 57
Study 25654366 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospitalization
Number of subjects: 57
Study 24634944 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Number of subjects: 92
Study 24634944 — intervention group
Group type: COMPARATOR
Intervention: Control (no phlebotomy)
Number of subjects: 92
Study 21205302 — intervention group
Group type: EXPERIMENTAL
Intervention: Masihambisane intervention (peer mentor-led sessions)
Number of subjects: 1200
Study 21205302 — intervention group
Group type: COMPARATOR
Intervention: Standard care PMTCT control condition
Number of subjects: 1200
Study 18503652 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body relaxation
Number of subjects: 118
Study 18503652 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw relaxation
Number of subjects: 118
Study 18503652 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 118
Study 18503652 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study 17119709 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 12
Study 17119709 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 12
Study 14514592 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.75 pmol x kg(‐1) x min(‐1))
Number of subjects: 8
Study 14514592 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 14514592 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 8
Study 11590117 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated perceptual thresholds for left/right outward radial optic flow discrimination in AD patients
Number of subjects: 36
Study 11590117 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of elevated optic flow thresholds with visuospatial function tests
Number of subjects: 36
Study 11590117 — intervention group
Group type: EXPERIMENTAL
Intervention: Global pattern perceptual deficits
Number of subjects: 36
Study 9748131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonradiolabeled 3F8
Number of subjects: 95
Study 9748131 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-labeled 3F8 (8-28 mCi/kg) with autologous bone marrow rescue
Number of subjects: 95
Study 9748131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nonradiolabeled and 131I-labeled 3F8
Number of subjects: 95
Study 9748131 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F8 treatment
Number of subjects: 95
Study 9748131 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2 expression
Number of subjects: 95
Study 9748131 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2 expression persistence
Number of subjects: 95
Study 8040406 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for 2 weeks
Number of subjects: 67
Study 8040406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 2493756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (2 mg per dose) by MDI
Number of subjects: 32
Study 2493756 — intervention group
Group type: COMPARATOR
Intervention: Placebo by MDI
Number of subjects: 32
Study 1097921 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at standard acupuncture points
Number of subjects: 40
Study 1097921 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment at placebo points
Number of subjects: 40
Study 1097921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 40
Study 31567321 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope
Number of subjects: 367
Study 31567321 — intervention group
Group type: COMPARATOR
Intervention: Optiscope video stylet
Number of subjects: 367
Study 30045159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy claims adherence (PDC)
Number of subjects: 682
Study 30045159 — intervention group
Group type: EXPERIMENTAL
Intervention: GlowCap adherence (GC)
Number of subjects: 682
Study 30045159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PDC and GC adherence
Number of subjects: 682
Study 30045159 — intervention group
Group type: COMPARATOR
Intervention: PDC alone
Number of subjects: 682
Study 29184630 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope flap (Group A)
Number of subjects: 25
Study 29184630 — intervention group
Group type: COMPARATOR
Intervention: Triangular flap (Group B)
Number of subjects: 25
Study 29184630 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 25
Study 24643755 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched beverage
Number of subjects: 15
Study 24643755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23219310 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 500mg orally twice daily for 28 days
Number of subjects: 9
Study 23219310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 23219310 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 9
Study 21787080 — intervention group
Group type: EXPERIMENTAL
Intervention: Written communication tool to facilitate doctor-patient communication
Number of subjects: 180
Study 21787080 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 180
Study 21787080 — intervention group
Group type: EXPERIMENTAL
Intervention: Written communication tool
Number of subjects: 180
Study 19567121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-duct plus tri-structure method
Number of subjects: 10492
Study 19567121 — intervention group
Group type: COMPARATOR
Intervention: Tri-duct method
Number of subjects: 10492
Study 16779983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-patient counseling
Number of subjects: 0
Study 16779983 — intervention group
Group type: COMPARATOR
Intervention: Written literature
Number of subjects: 0
Study 16779983 — intervention group
Group type: COMPARATOR
Intervention: Educational video
Number of subjects: 0
Study 15569037 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 12
Study 15569037 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 25 mg
Number of subjects: 12
Study 15569037 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 12
Study 15569037 — intervention group
Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 12
Study 15569037 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Promethazine
Number of subjects: 12
Study 11568132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude warm (HW) training
Number of subjects: 20
Study 11568132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-altitude warm training
Number of subjects: 20
Study 11568132 — intervention group
Group type: COMPARATOR
Intervention: High-altitude cool training
Number of subjects: 20
Study 11568132 — intervention group
Group type: COMPARATOR
Intervention: Low-altitude cool training
Number of subjects: 20
Study 11568132 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials
Number of subjects: 20
Study 11568132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-altitude warm training
Number of subjects: 20
Study 9418642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy, local irradiation, limb salvage surgery, prophylactic whole lung irradiation
Number of subjects: 130
Study 9418642 — intervention group
Group type: EXPERIMENTAL
Intervention: Local irradiation of the affected site
Number of subjects: 130
Study 9418642 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic response to preoperative multidisciplinary therapy
Number of subjects: 130
Study 9418642 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic whole lung irradiation
Number of subjects: 130
Study 9418642 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group
Number of subjects: 130
Study 31713082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose injection (1% lidocaine with 20% dextrose, 1 mL)
Number of subjects: 49
Study 31713082 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (1% lidocaine with saline, 1 mL)
Number of subjects: 49
Study 31713082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dextrose and Saline)
Number of subjects: 49
Study 28029114 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 µg folic acid and 500 µg vitamin B12 supplementation
Number of subjects: 2919
Study 28029114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-supplemented group)
Number of subjects: 2919
Study 28029114 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine
Number of subjects: 2919
Study 28029114 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 2919
Study 28029114 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin B12
Number of subjects: 2919
Study 28029114 — intervention group
Group type: EXPERIMENTAL
Intervention: Holotranscobalamin
Number of subjects: 2919
Study 25011384 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise group
Number of subjects: 110